文献速递主动脉疾病

血管内移植物治疗与药物治疗无并发症B型主动脉夹层的系统综述与Meta分析

Systematic review and meta-analysis of current evidence in endograft therapy vs medical treatment for uncomplicated type B aortic dissection.
PubMed 文献 · J Vasc Surg · 2022-04-04

该系统综述与Meta分析纳入11篇文章中的7项观察性研究和2项随机对照研究,共15,066例无并发症Stanford B型主动脉夹层患者(1518例接受TEVAR)。早期TEVAR组与BMT组在主动脉破裂、逆行性夹层、截瘫/轻截瘫、再干预、主动脉相关死亡及全因死亡方面无显著差异;长期TEVAR组上述不良事件发生率显著低于BMT组,且促进胸段假腔完全血栓形成和主动脉重塑。

要点

  • 早期TEVAR组与BMT组在主动脉破裂、逆行性夹层、截瘫/轻截瘫、再干预、主动脉相关死亡及全因死亡方面无显著差异。
  • 长期TEVAR组主动脉破裂、再干预、主动脉相关死亡及全因死亡发生率显著低于BMT组。
  • TEVAR显著促进胸段假腔完全血栓形成和主动脉重塑;若推迟早期TEVAR,密切随访至关重要。

核心结论

  • 早期TEVAR治疗无并发症Stanford B型主动脉夹层并未优于BMT,但实施TEVAR对改善长期预后是必要的;若推迟早期TEVAR,密切随访对于及时再干预至关重要。

研究设计与样本

  • 对评估TEVAR与BMT治疗无并发症Stanford B型主动脉夹层相对获益与危害的所有可用随机对照试验和观察性研究进行Meta分析,纳入来自11篇文章的7项观察性研究和2项随机对照研究,共15,066例患者(1518例TEVAR)。
  • 主要终点包括早期不良事件、长期不良事件和主动脉重塑;估计风险差(RD)或比值比(OR)及95%置信区间(CI),根据50%异质性阈值选用随机效应模型或固定效应模型。

主要发现

  • 早期结局方面,TEVAR组与BMT组在主动脉破裂、逆行性夹层、截瘫/轻截瘫、再干预、主动脉相关死亡和全因死亡方面无显著差异。
  • 长期TEVAR组相较BMT组主动脉破裂发生率显著更低(OR 0.26,95%CI 0.16-0.42,P<.05;异质性P=.90,I²=0%)。
  • 长期TEVAR组相较BMT组再干预发生率显著更低(OR 0.45,95%CI 0.26-0.75,P<.05;异质性P=.17,I²=41%)。
  • 长期TEVAR组相较BMT组主动脉相关死亡发生率显著更低(OR 0.27,95%CI 0.18-0.42,P<.05;异质性P=.61,I²=0%)。
  • 长期TEVAR组相较BMT组全因死亡发生率显著更低(OR 0.52,95%CI 0.42-0.66,P<.05;异质性P=.05,I²=53%)。

临床怎么用

  • 作者认为,早期TEVAR治疗无并发症Stanford B型主动脉夹层并未优于BMT,但实施TEVAR对改善长期预后是必要的。
  • 作者认为,若推迟早期TEVAR,密切随访对于及时再干预至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Best medical therapy (BMT) should be recommended for treating uncomplicated Stanford type B aortic dissection (uSTBAD), whereas thoracic aortic endovascular repair (TEVAR) has been controversial for uSTBAD. METHODS: In this paper, a meta-analysis was conducted on all available randomized controlled trials and observational studies that evaluated the relative benefits and harms of TEVAR and BMT for the management of patients suffering from uSTBAD. Primary endpoints consisted of early adverse events, long-term adverse events, and aortic remodeling. In addition, risk differences (RDs) or odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. The random-effects model or the fixed-effects model was used in accordance with the 50% heterogeneity threshold. RESULTS: Seven observational studies and two randomized controlled studies from 11 articles that contained 15,066 patients with uSTBAD (1518 TEVARs) met the inclusion criteria. For early outcomes, no significant differences were found between the TEVAR group and the BMT group in aortic rupture, retrograde dissection, paraplegia/paraparesis, reintervention, aorta-related death, and all-cause death. In the long run, the TEVAR group was found to have a significantly lower incidence of adverse events, which included aortic rupture (OR, 0.26; 95% CI, 0.16-0.42; P < .05; heterogeneity: P = .90, I2 = 0%), reintervention (OR, 0.45; 95% CI, 0.26-0.75; P < .05; heterogeneity: P = .17, I2 = 41%), aorta-related death (OR, 0.27; 95% CI, 0.18-0.42; P < .05; heterogeneity: P = .61, I2 = 0%), and all-cause death (OR, 0.52; 95% CI, 0.42-0.66; P < .05; heterogeneity: P = .05, I2 = 53%) as compared with the BMT group. Moreover, in compared with BMT, TEVAR was found to significantly contribute to the complete thrombosis of thoracic false lumen (OR, 55.34; 95% CI, 34.32-89.21; P < .05; heterogeneity: P = .97, I2 = 0%), and aortic regression (true lumen expansion and false lumen shrinkage). CONCLUSIONS: Although early endovascular repair of uSTBAD does not outperform BMT, its implementation is found to be necessary to facilitate the long-term prognosis. Accordingly, if early TEVAR is to be deferred, close follow-up is critical to allow for timely reintervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wang J, Jin T, Chen B, et al. Systematic review and meta-analysis of current evidence in endograft therapy vs medical treatment for uncomplicated type B aortic dissection. J Vasc Surg. 2022. PMID: 35390485. doi:10.1016/j.jvs.2022.03.876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。